GlassScriptPhysician profile
Matthew D Rogers
NPI 1427376748
$2,117.34
in general payments reported to CMS, 2019-2025
27 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $136 · 2021: $24.28 · 2022: $207 · 2023: $205 · 2024: $432 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $405.24 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $321.72 | 2019-2025 | Provenge |
| Pfizer INC. | $225.02 | 2019-2025 | |
| Janssen Biotech, INC. | $141.15 | 2019-2025 | Erleada, Akeega |
| Merck Sharp & Dohme LLC | $109.01 | 2023 | Lynparza |
| Intuitive Surgical, INC. | $96.89 | 2022 | |
| Astellas Pharma US INC | $83.19 | 2019-2025 | Xtandi |
| Boston Scientific Corporation | $81.41 | 2022-2024 | Tria Firm, Lumenis Pulse 120h |
| Medtronic, INC. | $73.53 | 2024 | Interstim |
| Myriad Genetic Laboratories, INC. | $68.72 | 2023-2025 | Prolaris |
| Novartis Pharmaceuticals Corporation | $59.87 | 2025 | |
| Abbvie INC. | $59.30 | 2019-2024 | |
| Allergan, INC. | $45.80 | 2019-2020 | |
| Photocure INC | $40.04 | 2019 | |
| Karl Storz Endoscopy-America | $37.65 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $33.42 | 2020-2022 | |
| Procept Biorobotics Corporation | $31.97 | 2025 | |
| Urovant Sciences INC | $31.93 | 2022 | |
| Antares Pharma, INC. | $30.73 | 2019-2020 | |
| Blue Earth Diagnostics | $23.13 | 2019 | |
| Teleflex LLC | $22.30 | 2025 | Barrigel |
| Urogen Pharma, INC. | $18.75 | 2025 | |
| Millicent US INC | $17.00 | 2024 | Intrarosa |
| Tolmar Pharmaceuticals, INC. | $15.43 | 2022 | |
| Tolmar, INC. | $15.25 | 2025 | Jatenzo, Eligard |
| Olympus America INC. | $14.78 | 2020 | |
| Medtronic USA, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.